ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.29
31.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc
Cost of Revenue
ACADIA Pharmaceuticals Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
Cost of Revenue
-$77.9m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$12.9B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-13%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-36%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-25%
|
|
ACADIA Pharmaceuticals Inc
Glance View
ACADIA Pharmaceuticals Inc., nestled in the heart of biopharmaceutical innovation, has carved a niche as a trailblazer in tackling neurological and central nervous system disorders. The company's journey pivotally surrounds its flagship product, NUPLAZID (pimavanserin), which was approved by the FDA in 2016. Designed to address the psychosis associated with Parkinson’s disease, NUPLAZID opened new therapeutic doors, addressing a critical unmet medical need and improving patients’ quality of life. Leveraging this milestone, ACADIA has strategically focused on developing innovative therapies, extending its research into potential treatments for schizophrenia, major depressive disorders, and other neuropsychiatric conditions, thus widening its revenue streams and research portfolios. The company's financial engine is fueled primarily by sales of NUPLAZID, which has stood as a steady pillar in generating revenues. To amplify its growth trajectory, ACADIA emphasizes expanding NUPLAZID's usability through rigorous clinical trials aimed at securing approvals for additional indications. Concurrently, the company actively explores partnerships and acquisitions to broaden its pipeline, inaugurating an aspirational pursuit to revolutionize mental health treatment. With a keen eye on demographic trends and the increasing prevalence of CNS disorders globally, ACADIA Pharmaceuticals aligns its business operations not just on curing ailments, but on redefining health paradigms, thus reinforcing its sustainability in the competitive biopharmaceutical landscape.
See Also
What is ACADIA Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-77.9m
USD
Based on the financial report for Sep 30, 2024, ACADIA Pharmaceuticals Inc's Cost of Revenue amounts to -77.9m USD.
What is ACADIA Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-33%
Over the last year, the Cost of Revenue growth was -197%. The average annual Cost of Revenue growth rates for ACADIA Pharmaceuticals Inc have been -54% over the past three years , -33% over the past five years .
You don't have any saved screeners yet
